BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Manual for Instructive Application for Youngsters - 2Step by step instructions to Keep up with the Life span of Your Kona SUV's Battery Duration
- 3A Sweet Choice: Pick Your #1 Cake!
- 4The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- 5Manual for Shrewd Home Lighting Framework: Lights up Your Space
- Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat!
- Instructions to Warmly greet Discretion and Thoughtfulness
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- The Delight of Perusing: Book Proposals for Each Class
- 2 ways you can conserve the water used to make your food
- Dependable Savvy Locks to Update Your Home Security
- Michael Jordan donates $10M to North Carolina medical center in honor of his mother
- First SpaceX booster for upgraded Starship fails during test in Texas
